Is Alzheimer’s research focusing on the wrong target?
In Medscape, Dr. Steven DeKosky weighs in on the Alzheimer's research field's longtime focus on amyloid.
Posts tagged as
Steven DeKosky
Blood tests for phosphorylated tau 217 identify people with presymptomatic Alzheimer’s disease
In Neurology Today, Dr. Steven DeKosky weighed in on a new meta-analysis showing that levels of phosphorylated tau 217 accurately predicted the presence of amyloid in the cortex of participants.
Popular diabetes medications may protect against Alzheimer’s disease
Dr. Steven DeKosky co-authored study in JAMA Neurology showing link between two diabetes drug classes and lower Alzheimer's risk in Type 2 diabetes patients.
MBI deputy director receives national Alzheimer’s Association award
UF neurologist Dr. Steven T. DeKosky honored for work to bolster global Alzheimer’s research network
Here’s where the prevalence of Alzheimer’s dementia is highest and lowest
MBI deputy director Dr. Steven DeKosky commented for article in Neurology Today.
Alzheimer’s disease is partly genetic − studying the genes that delay decline in some may lead to treatments for all
In The Conversation, UF neuroscientist Dr. Steven DeKosky explains new discoveries with treatment implications.
Medical community hopeful following FDA’s accelerated approval for Alzheimer’s disease treatment
Drs. Steven DeKosky and Glenn Smith discuss Lecanemab for WUFT article.
MBI deputy director surpasses 100K citations
Dr. Steven DeKosky has been cited over 100K times, per Google Scholar.
Predicting cognitive decline after dementia diagnosis
Dr. Steven DeKosky provides indicators to help “guestimate” rate of cognitive decline.
Dementia patients are at greater risk for COVID-19
Conversation article co-authored by Drs. Steven DeKosky and Michael Jaffee discusses new research about dementia and COVID-19 risk.
